Has Kevin Cox received payments from drug or device companies?

Yes. Drug and device makers reported $2,886,649 in general payments to Kevin Cox across 207 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Kevin Cox did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Kevin Cox come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Kevin Cox

Child & Adolescent Psychiatry · Ojai, CANPI 1538214614

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $2,839,542 of the $2,886,649 with a category attached, or 98.4%. Otsuka Pharmaceutical Development & Commercialization, Inc. accounts for 99.7% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2022 at $946,103 and has fallen 82.3% since, to $167,700 in 2023. Among child & adolescent psychiatry clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,886,649in general payments, 2019–2025

Across 207 payments — averaging $13,945 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Otsuka Pharmaceutical Development & Commercialization, Inc.$2.9M
Biohaven Pharmaceuticals, Inc.$6K
Biohaven Pharmaceutical Holding Company Ltd.$2K

$48,974in research payments, 2019–2025

Across 5 payments — averaging $9794.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Otsuka Pharmaceutical Development & Commercialization, Inc.$49K

What the payments were for

Consulting fees$2,839,54298%
Travel & lodging$44,7672%
Food & beverage$2,3400%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Otsuka Pharmaceutical Development & Commercialization, Inc.	202	$2,877,859
Biohaven Pharmaceuticals, Inc.	2	$6,375
Biohaven Pharmaceutical Holding Company Ltd.	3	$2,415

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

REXULTI$2,874,828

How this compares

$2,886,649 in reported general payments places this provider in the 95th percentile of 434 child & adolescent psychiatry providers in California.

See all child & adolescent psychiatry providers in California →

Other child & adolescent psychiatry in Ojai

Sukhjit BrarFresno$283K
Manpreet SinghSacramento$104K
Ihab SolimanCorona del Mar$93K
Syed NaqviLos Angeles$69K
Ellen HeynemanSan Diego$62K
Mark McDonaldLos Angeles$31K
James HartmanDanville$21K
Mohsin KhaliqueSan Ramon$20K
Mansoor ZuberiWalnut Creek$16K
Michael McManusSan Diego$15K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →